Regulatory press release

Xintela AB Interim Report January - September 2022

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

Third quarter 2022 for the group
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 14,456 (loss: 15,892)
» Loss per share* was SEK 0.11 (loss: 0.20)

First nine months 2022 for the group
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 49,781 (loss: 42,591)
» Loss per share* was SEK 0.36 (loss: 0.53)

Third quarter 2022 for the parent company
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 9,197 (loss: 10,910)
» Loss per share* was SEK 0.07 (loss: 0.13)

First nine months 2022 for the parent company
» Income amounted to TSEK 0 (0)
» Loss before and after tax totalled TSEK 31,786 (loss: 31,752)
» Loss per share* was SEK 0.23 (loss: 0.39)
» At June 30, 2022, the equity/assets ratio** was 59 % (77)

Significant events in the third quarter of 2022
» Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers (July 5, 2022)
» Xintela publishes the outcome of the rights issue and decides on a directed new issue of SEK 10 million (July, 18 2022)
» Notice of Extraordinary General Meeting in Xintela AB (July, 18 2022)
» Per Norlén to step down as Targinta CEO (August 2, 2022)
» Bulletin from the Extraordinary General Meeting in Xintela AB (August 3, 2022)
» Statement from the board of Xintela on the occasion of Flerie Invest AB’s mandatory cash take-over bid offer (August 31, 2022)
» Targinta presents positive preclinical data on the antibody-drug conjugate TARG9 (September 1, 2022)
» Xintela starts clinical study with XSTEM for difficult-to-heal leg ulcers (September 20, 2022)
» Targinta appoints Peter Ekolind as acting CEO (September 22, 2022)
» Xintela completes dosing of XSTEM first dose level in knee osteoarthritis clinical study (September 30, 2022)

Significant events after the end of the period
» Notice to Extraordinary General Meeting of Xintela AB (October 26, 2022)
» Xintela secures financing of SEK 25 million and decides on a targeted issue of convertibles (October 26, 2022)
» Xintela proposes Thomas Eldered as new Board member (October 31, 2022)
» Xintela starts next dose level of XSTEM in knee osteoarthritis clinical study (November 9, 2022)
» Targinta plans Phase 0 clinical study (November 24, 2022)

The complete interim report is available for download below and on the company’s website www.xintela.se/en/investors#reports

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.